Aurobindo Pharma Share Price
14 Aug, 2026 3:55 PM (IST)
Aurobindo Pharma Performance
- Today's Low
- ₹1,622
- Today's High
- ₹1,670
- 52 Week Low
- ₹1,016
- 52 Week High
- ₹1,682
- Open Price₹1,662
- Previous Close₹1,663
- Volume852,565
- 50 DMA₹1,553.00
- 100 DMA₹1,479.70
- 200 DMA₹1,382.40
Aurobindo Pharma Chart
Investment Returns
- Over 1 Month + 4.64%
- Over 3 Month + 7.3%
- Over 6 Month + 41.59%
- Over 1 Year + 49.7%
Smart Investing Starts Here Start SIP with Aurobindo Pharma for Steady Growth!
Aurobindo Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 23.9
- PEG Ratio
- 1.5
- Market Cap Cr
- 94,212
- P/B Ratio
- 2.5
- Average True Range
- 39.4
- EPS
- 67.8
- Dividend Yield
- 0
- MACD Signal
- 30.1
- RSI
- 55.68
- MFI
- 82.17
Latest Stock News Updates
Intimation of participation of officials of the Company in investors / analysts meet to be held on August 19, 2026
- BSE India
- 1 day 15 hours ago
Aurobindo Pharma on Friday said the US health regulator has issued a warning letter to a formulation manufacturing facility of its arm, Eugia Pharma Specialities Ltd, in Telangana. In May this year the company had stated that the US Food and Drug Administration (USFDA) inspected Unit-I, a formulation manufacturing facility of Eugia Pharma Specialities Ltd located at Telangana from February 16 to February 27, 2026. The inspection had concluded with four observations and the USFDA had determined the facility as 'official action indicated' (OAI). "Subsequent to OAI, the unit has received a warning letter," Aurobindo Pharma said in a regulatory filing. There is no impact on the existing supplies to the US markets, it added. The company further said the Unit I of Eugia Pharma Specialities Ltd, is contributing to about 2 per cent to company's overall group revenue. Aurobindo Pharma said it remains committed to working closely with the US FDA and continues to enhance its compliance on a
- Business Standard
- 1 day 17 hours ago
Intimation of receipt of warning letter from US FDA by Unit 1 of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.
- BSE India
- 1 day 21 hours ago
Aurobindo Pharma Financials
Aurobindo Pharma Technicals
EMA & SMA
- Bearish Moving Average 5
- Bullish Moving Average 11
- 20 Day
- ₹1,604.00
- 50 Day
- ₹1,553.00
- 100 Day
- ₹1,479.70
- 200 Day
- ₹1,382.40
Resistance and Support
- R3 1,702.20
- R2 1,686.10
- R1 1,654.10
- S1 1,606.00
- S2 1,589.90
- S3 1,557.90
Aurobindo Pharma Corporate Actions - Bonus, Splits, Dividends
Aurobindo Pharma F&O
About Aurobindo Pharma
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. View More- NSE Symbol
- AUROPHARMA
- BSE Symbol
- 524804
- ISIN
- INE406A01037
Similar Stocks to Aurobindo Pharma
Popular Stocks
Aurobindo Pharma FAQs
Aurobindo Pharma share price is ₹1,622 As on 16 August, 2026 | 07:25
The Market Cap of Aurobindo Pharma is ₹94211.8 Cr As on 16 August, 2026 | 07:25
The P/E ratio of Aurobindo Pharma is 23.9 As on 16 August, 2026 | 07:25
The PB ratio of Aurobindo Pharma is 2.5 As on 16 August, 2026 | 07:25
The 52 week High & Low of Aurobindo Pharma is ₹1682.4/₹1016.1 respectively As on 16 August, 2026 | 07:25
Aurobindo Pharma has an operating revenue of Rs.24,010.31 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 30% is great. Many brokers and analysts have recommended 'Buy' on the stock.
Aurobindo Pharma Ltd. has declared 40 dividends since May 10, 2000.
The stock price CAGR of Aurobindo Pharma for 10 Years is 30%, 5 Years is 0%, 3 Years is -3%, 1 Year is -25%.
Aurobindo Pharma has an ROE of 24% which is exceptional.
Aurobindo Pharma has a reasonable debt to equity of 1%, which signals a healthy balance sheet.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.